592217 Dis closed is the use of an effective amount of liposomal amikacin in the preparation of a formulation for the treatment of a pulmonary disorder in a patient, wherein: the formulation comprises a lipid and amikacin, the lipid to amikacin ratio is about 0.3 to about 1.0 by weight, the formulation is for administration to the patient for at least two treatment cycles, wherein the treatment cycle comprises an administration period of the formulation of 15 to 75 days, followed by an off period of 15 to 75 days； and the effective dose of the formulation comprises 100 to 2500 mg of amikacin daily during the administration period, and the formulation is for administration to the patient by nebulisation.
